Crestline Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $49.1M | Sell |
1,910,732
-300,000
| -14% | -$6.16M | 91.9% | 1 |
|
|
2026
Q1 | $42.4M | Sell |
2,210,732
-600,000
| -21% | -$11.9M | 91.74% | 1 |
|
|
2025
Q4 | $46.4M | Sell |
2,810,732
-600,000
| -18% | -$10.1M | 87.02% | 1 |
|
|
2025
Q3 | $49.5M | Sell |
3,410,732
-450,000
| -12% | -$6.47M | 85.26% | 1 |
|
|
2025
Q2 | $54M | Sell |
3,860,732
-300,000
| -7% | -$4.22M | 86.33% | 1 |
|
|
2025
Q1 | $56.6M | Sell |
4,160,732
-150,000
| -3% | -$2.87M | 89.45% | 1 |
|
|
2024
Q4 | $87.9M | Sell |
4,310,732
-150,000
| -3% | -$3.84M | 2.92% | 3 |
|
|
2024
Q3 | $130M | Sell |
4,460,732
-300,000
| -6% | -$7.44M | 6.75% | 3 |
|
|
2024
Q2 | $111M | Sell |
4,760,732
-450,000
| -9% | -$8.64M | 8.6% | 2 |
|
|
2024
Q1 | $107M | Sell |
5,210,732
-450,000
| -8% | -$8.46M | 9.45% | 1 |
|
|
2023
Q4 | $121M | Sell |
5,660,732
-300,000
| -5% | -$5.94M | 10.35% | 1 |
|
|
2023
Q3 | $123M | Sell |
5,960,732
-150,000
| -2% | -$3.8M | 14.32% | 1 |
|
|
2023
Q2 | $180M | Sell |
6,110,732
-300,000
| -5% | -$8.44M | 18.83% | 1 |
|
|
2023
Q1 | $148M | Sell |
6,410,732
-450,000
| -7% | -$12.4M | 17.54% | 1 |
|
|
2022
Q4 | $191M | Sell |
6,860,732
-300,000
| -4% | -$8.93M | 27.96% | 1 |
|
|
2022
Q3 | $220M | Sell |
7,160,732
-300,000
| -4% | -$9.75M | 29.71% | 1 |
|
|
2022
Q2 | $220M | Hold |
7,460,732
| – | – | 28.65% | 1 |
|
|
2022
Q1 | $240M | Sell |
7,460,732
-244,307
| -3% | -$8.41M | 28.78% | 1 |
|
|
2021
Q4 | $344M | Hold |
7,705,039
| – | – | 25.68% | 1 |
|
|
2021
Q3 | $389M | Sell |
7,705,039
-430,442
| -5% | -$24.3M | 36.56% | 1 |
|
|
2021
Q2 | $638M | Sell |
8,135,481
-1,849,355
| -19% | -$114M | 55.02% | 1 |
|
|
2021
Q1 | $570M | Sell |
9,984,836
-9,477,664
| -49% | -$634M | 72.4% | 1 |
|
|
2020
Q4 | $339M | Buy |
19,462,500
+7,260,866
| +60% | +$439M | 35.95% | 1 |
|
|
2020
Q3 | $437M | Sell |
12,201,634
-1,443,247
| -11% | -$43.5M | 64.45% | 1 |
|
|
2020
Q2 | $330M | Sell |
13,644,881
-1,922,855
| -12% | -$45.2M | 60.47% | 1 |
|
|
2020
Q1 | $273M | Sell |
15,567,736
-3,894,764
| -20% | -$81.2M | 78.45% | 1 |
|
|
2019
Q4 | $339M | Hold |
19,462,500
| – | – | 43.9% | 1 |
|
|
2019
Q3 | $298M | Hold |
19,462,500
| – | – | 48.02% | 1 |
|
|
2019
Q2 | $404M | Hold |
19,462,500
| – | – | 54.41% | 1 |
|
|
2019
Q1 | $452M | Hold |
19,462,500
| – | – | 98.01% | 1 |
|
|
2018
Q4 | $402M | Sell |
19,462,500
-1,111,799
| -5% | -$20.2M | 60.8% | 1 |
|
|
2018
Q3 | $447M | Hold |
20,574,299
| – | – | 41.41% | 1 |
|
|
2018
Q2 | $314M | Hold |
20,574,299
| – | – | 32.97% | 1 |
|
|
2018
Q1 | $405M | Buy |
20,574,299
+1
| +0% | +$21 | 50.4% | 1 |
|
|
2017
Q4 | $322M | Buy |
+20,574,298
| New | +$370M | 32.96% | 2 |
|
Other funds holding DNLI
Crestline Management's DNLI Position: Q2 2026 in Review
Crestline Management reduced its Denali Therapeutics (DNLI) stake by 14% in Q2 2026, selling an estimated $6.16M and leaving 1,910,732 shares worth $49.1M. The position accounts for 91.9% of the portfolio, ranked #1.
Crestline Management first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. The position peaked at $638M in Q2 2021. 293 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Crestline Management held 1,910,732 shares of Denali Therapeutics worth $49.1M as of Q2 2026.
- Crestline Management sold 300,000 Denali Therapeutics shares in Q2 2026, an estimated $6.16M.
- Denali Therapeutics made up 91.9% of Crestline Management's portfolio in Q2 2026, its #1 holding.
- Crestline Management first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Crestline Management's Denali Therapeutics position peaked at $638M in Q2 2021.
- 293 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Crestline Management's 13F filing for Q2 2026, filed 14 Aug 2026.